Business
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.","length":373,"tagName":"p"},{"type":"text","content":"Poster 244P : Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation1","length":124,"tagName":"p"},{"type":"text","content":"Joint lead author Dr. Pei-Hsing Chen, Assistant Professor, Surgical Department, National Taiwan University Hospital, Taipei City, Taiwan, said:","length":143,"tagName":"p"},{"type":"text","content":""A key finding from this study was that measuring preoperative H3K27Me3-nucleosomes using Volition's simple blood test allows us to identify which Non Small Cell Lung Cancer patients are most likely to benefit from closer follow-ups or secondary cancer treatment.","length":272,"tagName":"p"},{"type":"text","content":""While high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes, low H3K27me3 levels indicated significantly better outcomes.","length":168,"tagName":"p"},{"type":"text","content":""Volition's Nu.Q® H3K27Me3-nucleosome levels may also help identify micro-metastatic disease and support systemic treatment decision-making in high-risk patients.","length":171,"tagName":"p"},{"type":"text","content":""The Nu.Q® Cancer technology supports a practical approach to empower clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey."","length":215,"tagName":"p"},{"type":"text","content":"Dr Andrew Retter, Medical Consultant, Volition, said:","length":53,"tagName":"p"},{"type":"text","content":""Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring.","length":189,"tagName":"p"},{"type":"text","content":""Research conducted by our long-term collaborators in Taiwan and Lyon1-4 consistently demonstrates that our Nu.Q® Cancer technology empowers clinicians to...